Axol Bioscience Ltd.

Download the new Axol Bioscience Sporadic Alzheimer’s Disease Line Collection brochure Axol Bioscience, in partnership with StrataStem, has announced the release of a collection of induced pluripotent stem cell (iPSC) lines derived from patients with sporadic Alzheimer’s Disease (sAD). This ‘Axol Bioscience Sporadic Alzheimer’s Disease Line Collection’ is available for use in Axol’s custom iPSC-derived cell manufacturing program and represents a significant advancement in the tools available for pre-clinical in vitro model building and drug discovery research. Key highlights of the collection: ? Custom manufacturing capabilities for multiple neural cell types, including cortical excitatory neurons, cortical inhibitory neurons, microglia, and astrocytes ? Complete ApoE genotype profiling, including representation of E2/E3, E3/E3, E3/E4, and E4/E4 variants ? Rigorous donor screening and selection criteria and quality control of manufactured cells ? Flexible delivery options, including direct shipment to clients or third-party service providers ? Scalable and customizable manufacturing processes To learn more about it, download the new Axol Bioscience Sporadic Alzheimer’s Disease Line Collection brochure here: https://hubs.la/Q03cGvcP0 For more information, contact us at [email protected] #AlzheimersDisease #AD #iPSCs #CustomManufacturing

WEBINAR ALERT! Join Duncan Borthwick PhD Borthwick, Head of Sales & Marketing, and Helene Lemenager, PhD, Head of Dermo-Cosmetics in our LinkedIn webinar on April 3rd at 4 PM, where they’ll discuss the growing role of iPSC-derived cells in dermatology and cosmetics research. In this session, they’ll talk about: ? how iPSC technology is a powerful tool for dermatology research and testing, enabling the creation of human skin models that closely mimic the physiology and responses of skin. ? iPSC-derived cell types we manufacture for cosmetics research, toxicology and drug discovery ? our service project offerings for a wide range of tests, using in vitro models This discussion will be particularly valuable for anyone working in dermatology and cosmetics research and those looking to incorporate iPSC-based models into their research. Hélène will be attending In-Cosmetics Global from the 8th to the 10th of April in Amsterdam and is happy to discuss your dermatology challenges with you. Contact?[email protected] to arrange a meeting with her. Register for this webinar below. #Dermatology #CosmeticsResearch #SkinModels #Webinar

innoVitro and Axol Bioscience: Atrial Fibrillation model using axoCells human iPSC-derived Atrial Cardiomyocytes Come along to see Bettina Lickiss from innoVitro (booth #732) present their new poster in collaboration with Axol, “AF on Demand : A Human iPSC-Derived Screening Assay Targeting Atrial Fibrillation". Abstract Number/Poster Board number: #2173 Key highlights include: ? Antiarrhythmic drugs ibutilide, dofetilide and sotalol are known therapeutics for restoring normal heart rhythm in AF. ? All three compounds show respective EFP duration prolonging effects in the here presented in vitro disease model using our axoCells human iPSC-derived Atrial Cardiomyocytes ? This human-based disease model represents a significant advancement for atrial fibrillation research. It provides a human-relevant platform for identifying novel therapies with greater translational potential and accelerating the development of effective AF treatments. Stop by the poster and speak to Bettina or come by our booth #505. #SOT #iPSCs #cardiotoxicity #cardiomyocytes #DrugDiscovery #Collaboration

Don't forget to come and see us at SOT! It's the last day of the Society of Toxicology 64th Annual Meeting in Orlando! If you haven't already, then come and meet the team at Booth 505, and find out you could utilize our iPSC technology for your toxicity research and screening. We've had a busy few days at the meeting - here are some of our highlights: 1. Group Leader Jamie Bhagwan presented our new poster, “Differential responses of chamber-specific human iPSC-derived cardiomyocytes for in vitro cardiotoxicity studies.” Come and talk to Jamie to find out more about how we can help your cardiotoxicity work. 2. We launched our new media, MyoMax, a groundbreaking maturation media designed to enhance the maturity of iPSC-derived cardiomyocytes (CMs). MyoMax addresses the critical limitations of current in vitro cardiac models by fostering the development of more mature, more physiologically relevant CMs, ultimately improving the accuracy and reliability of cardiotoxicity studies and drug development. 3. The Axol team have been at booth 505 talking about toxicology challenges, and some of our key safety pharmacology areas: ? Chamber-specific cardiotoxicity models ? Sensory and cosmetic toxicology ? CNS toxicity Our new product, MyoMax is the result of feedback last year from scientists that immature CMs do not accurately recapitulate the response of adult CMs in cardiotoxicity and disease modelling studies. We decided to see how we could help, and produced MyoMax as a result. This year, we once again ask you, "iPSCs - What can we do to help?" If you're not at the meeting, but still want to find out more, or have a challenge we can help with, contact us on [email protected] #iPSCs #SOT #cardiotoxicity #neurotoxicity #MyoMax

The Axol team are busy, busy at the Society of Toxicology 64th Annual Meeting and ToxExpo. Come along to see Jamie Bhagwan present our new poster in collaboration with innoVitro, “Differential responses of chamber-specific human iPSC-derived cardiomyocytes for in vitro cardiotoxicity studies”. Abstract Number/Poster Board number: 4454/E289 Session Title: Stem Cell Biology and Toxicology Session Date and Time: 19MAR25 9:15:00 AM to 19MAR25 11:45:00 AM This informative poster includes: ? Characterization data from chamber-specific human iPSC-derived cardiomyocytes ? Chamber-specific contractility waveform differences ? Atrial-specific response to Carbachol (activator of IKACh) ? Opposing transient response to S-Bay K8644 (Ca2+ agonist) ? Performance data from MyoMax our new maturation media, showing enhanced metabolic maturation of human iPSC-derived cardiomyocytes Jamie will be joined by other members of the Axol team on booth 505. If you're attending SOT, make sure to join us for a chat, and to ask any questions about how Axol Bioscience can help you to unlock the benefits of iPSC technology for your toxicology studies. Not at SOT? Download the poster here: https://hubs.la/Q03cwSZ80 #SOT2025 #iPSCs #cardiotoxicity #cardiomyocytes #DrugDiscovery

We're in Orlando attending the Society of Toxicology 64th Annual Meeting and ToxExpo, talking to customers about how we can help solve their toxicology challenges. Cardiotoxicity, neurotoxicity and cosmetic toxicology are key areas for Axol Bioscience and we're excited to get the opportunity to discuss our work unlocking iPSC technology for in vitro toxicity models. Teodora Popovici, Jack C., Jamie Bhagwan, and Steven Broadbent are attending from the Axol team. Come and talk to us on Booth 505. For those of you that can't attend, or if you want a preview of what we're doing, check out our booth tour. #iPSC #SOT2025 #cardiotoxicity #neurotoxcity

We're having a great time at SOT! If you're here, make sure to visit Booth #505 to discuss how Axol Bioscience can unlock iPSC technology for your in vitro toxicity models. We've also enjoyed catching up with our friends from innoVitro booth #732 who joined us today to discuss iPSC technology, and how we're helping researchers to build better in vitro cardiotoxicity models. If you'd like to discuss how we could unlock iPSC technology for your cardiotoxicity and neurotoxicity research, get in contact at [email protected] Bettina Lickiss Matthias Gossmann Steven Broadbent Jamie Bhagwan #SOT #iPSCs #CiPA #cardiotoxicity #neurotoxicity #DrugDiscovery

Download the new MyoMax Maturation Media brochure We are excited to announce the launch of MyoMax?, a groundbreaking maturation media designed to enhance the maturity of iPSC-derived cardiomyocytes (CMs). Current iPSC-based models used for cardiotoxicity studies and disease modeling often suffer from the functional immaturity of the cardiomyocytes. These cells typically resemble fetal developmental states, leading to inaccurate drug responses and compromised phenotypic representations. MyoMax? tackles this challenge by providing a specialized metabolic environment that promotes the development of more mature CMs which more faithfully recapitulate the responses of adult cardiac tissue. A more mature phenotype in iPSC-CMs is evidenced by: ? Morphology: Increased numbers of rod-shaped cells, with superior sarcomere alignment. ? Marker Expression: The expression of key maturity markers and absence of immaturity markers ? Metabolic Shift: More mature CMs undergo a shift from glucose to fatty acid metabolism ? Electrophysiology: shorter action potential durations and faster conduction velocities closely reflect the electrophysiological properties of mature cardiac tissue. To learn more about it, download the new MyoMax Maturation Media brochure here: https://hubs.la/Q03bTyTv0 For more information, contact us at [email protected] #MatureCardiomyocytes #NewMedia

WEBINAR ALERT! Want to learn more about the recently announced ‘Axol Bioscience Sporadic Alzheimer’s Disease Line Collection’? Join us for a LinkedIn webinar on 27th March at 4 PM. We have recently announced, in partnership with STRATASTEM LIMITED, the release of a collection of induced pluripotent stem cell (iPSC) lines derived from patients with sporadic Alzheimer’s Disease (sAD). This ‘Axol Bioscience Sporadic Alzheimer’s Disease Line Collection’ is available for use in Axol’s custom iPSC-derived cell manufacturing program and represents a significant advancement in the tools available for pre-clinical in vitro model building and drug discovery research. Join us in this webinar, where Duncan Borthwick PhD, our Head of Sales and Marketing, and Chris Ward, Director and Co-founder of StrataStem, will discuss the key benefits of this collection: ? Custom manufacturing capabilities for multiple neural cell types, including cortical excitatory neurons, cortical inhibitory neurons, microglia, and astrocytes ? Complete ApoE genotype profiling, including representation of E2/E3, E3/E3, E3/E4, and E4/E4 variants ? Rigorous donor screening and selection criteria and quality control of manufactured cells ? Flexible delivery options, including direct shipment to clients or third-party service providers ? Scalable and customizable manufacturing processes Register for this webinar below. If you have any questions, contact us at [email protected]. hashtag #AlzheimersDisease #AD #Webinar #iPSCs

If you're at the Society of Toxicology 64th Annual Meeting, come and say hello! Our team are ready and waiting at Booth 505 to talk about how you could utilize our iPSC technology for your toxicity research and screening. Group Leader Jamie Bhagwan will be presenting our new poster, “Differential responses of chamber-specific human iPSC-derived cardiomyocytes for in vitro cardiotoxicity studies.” Come and talk to Jamie to find out more about our cardiotoxicity work, and our new maturation media, MyoMax. Don't miss the opportunity to speak to us in person about our industry-leading work with human iPSCs in the toxicology space. If you're not at the meeting, but still want to find out more, contact us on [email protected] Steven Broadbent Jack C. Teodora Popovici #iPSCs #SOT #cardiotoxicity #neurotoxicity